ArticleArtificial organs2021
Blood purification with CytoSorb in critically ill COVID-19 patients: A case series of 26 patients.
Article in Artificial organs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- CytoSorb in patients with coronavirus disease 2019: A rapid evidence review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta-analysis of randomized controlled trials.Acta anaesthesiologica Scandinavica · 2022Pooled it
- Case Report: CytoSorb hemoadsorption as an adjunctive therapy in critically ill pregnant women with COVID-19 and acute kidney injury-a case series.Frontiers in medicine · 2025Article
- The use of CytoSorb hemoadsorption in critically ill patients: a narrative review.Frontiers in medicine · 2025Review
- Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy.Immunotherapy · 2024Article
- Hemoadsorption as Adjuvant Therapy in Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis.Biomedicines · 2023Review
- Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry.Critical care (London, England) · 2023Article
- Extracorporeal blood purification strategies in sepsis and septic shock: An insight into recent advancements.World journal of critical care medicine · 2023Review
- Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review.Frontiers in immunology · 2023Review
- Acute Kidney Injury and Blood Purification Techniques in Severe COVID-19 Patients.Journal of clinical medicine · 2022Review
- COVID-19 and Acute Kidney Injury.Critical care clinics · 2022Review
- Sepsis Management in Southeast Asia: A Review and Clinical Experience.Journal of clinical medicine · 2022Review
- Hemoperfusion: technical aspects and state of the art.Critical care (London, England) · 2022Review
- Blood purification in sepsis and COVID-19: what´s new in cytokine and endotoxin hemoadsorption.Journal of anesthesia, analgesia and critical care · 2022Review
- Activated Platelets and Platelet-Derived Extracellular Vesicles Mediate COVID-19-Associated Immunothrombosis.Frontiers in cell and developmental biology · 2022Review
- Blood purification could tackle COVID-19?Journal of intensive care · 2021Article
- Blood purification with CytoSorb in critically ill COVID-19 patients: A case series of 26 patients.Artificial organs · 2021Article
- Cytokine Hemoadsorption as Rescue Therapy for Critically Ill Patients With SARS-CoV-2 Pneumonia With Severe Respiratory Failure and Hypercytokinemia.Frontiers in medicine · 2021Article
- Blood Purification in Severe and Critical COVID-19 Patients: A Case Series of 5 Patients.Frontiers in public health · 2021Article
- The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences.Critical care research and practice · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe forms of the coronavirus disease 2019 (COVID-19) can progress to sepsis-like complications accompanied by "cytokine storm" for which the most effective treatment has not yet been established. Our study describes the results of CytoSorb hemoadsorption in COVID-19 patients treated on the intensive care unit (ICU). In this retrospective study, 26 patients with COVID-19 and acute respiratory distress syndrome (ARDS) were treated with hemoadsorption therapy. Pre-, and post-treatment values (clinical and laboratory) were compared. Data are expressed as mean (confidence intervals, CI), or median [interquartile ranges, IQR], as appropriate. Patients received 2 hemoadsorption treatments. This resulted in a significant decrease in norepinephrine requirements, and inflammatory marker plasma concentrations (procalcitonin, C-reactive protein, ferritin) when comparing pre versus post treatment levels. The PaO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.